Clinical Trial Update: Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant/adjuvant trial of darovasertib in ocular melanoma has completed enrollment, with St Vincent's Hospital, Sydney listed as sponsor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• Darovasertib (darovasertib)

Snippet

Sponsor: St Vincent's Hospital, Sydney | Conditions: Ocular Melanoma | Phase 2 | Status: COMPLETED